Biotechnology Venture Capital Valuations Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Biotechnology Venture Capital Valuations book. This book definitely worth reading, it is an incredibly well-written.
Biotechnology Venture Capital Valuations by Anonim Pdf
Biotechnology Venture Capital Valuations is an authoritative, insider's perspective on biotech venture capital for both the venture capitalist and the entrepreneur. Featuring partners, presidents, and CEOs of top venture capital and investment firms, Biotechnology Venture Capital Valuations provides best practices for venture capitalists and entrepreneurs at all stages of investment with a focus on determining valuations and structuring deals. These industry experts discuss their strategies for considering a biotech investment, locating investment opportunity, assessing risk, and negotiating with the entrepreneur, as well as offering different valuation methods for a variety of common scenarios. This book provides valuable insight for those investing capital as well as those needing it, including explanation of the different goals of the venture capitalist and entrepreneur, common mistakes made on both sides, and how best to establish a productive relationship between the two.
Valuation in Life Sciences by Boris Bogdan,Ralph Villiger Pdf
Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines.
Biotechnology Valuation & Investing by Jason Hsu,Dimitrios Iliopoulos Pdf
The selection of biotech stocks for investment is more difficult compared with the selection of other stocks and industries that possess historical data, since biotechnology is a recently new science. In the first edition of this book, we described the crucial parameters for the valuation of an early stage biotech company without a drug in the market. In this edition, we analyze novel financial models that can value stocks of biotech companies with products in the market or products under development (in pre-clinical and clinical studies). All of these parameters should be helpful to potential new investors when creating a stock portfolio that includes highly promising biotech companies. Our strategy of selecting highly promising stocks based on all parameters described in this book and of performing a basic financial modeling analysis with DFC and/or real options valuation models has proven very successful, as this strategy provides returns higher than 100% in most cases. In the first edition of this book, based on our strategy, we suggested that Juno Therapeutics and Kite Pharma were "hot" stocks. At that time, Kite's stock was $50.19, while Juno's stock was $54.21. Since then, Kite's stock reached $179.79, with the company acquired by Gilead for $11.9 billion, while Juno's stock reached $86.96, with the company acquired by Celgene for $9 billion. Furthermore, Moderna Therapeutics, a private company that we valued at $5.5 billion in 2016 based on our real options financial model, today has a $7.5 billion valuation. This newly revised and expanded version was written to help investors in the selection of biotech stocks based on different scientific and financial criteria.
Strategies for Biotechnology Venture Capital 2008/2009 by Dinesh Patel,Killu Tougu Sanborn,Fred A. Middleton Pdf
Strategies for Biotechnology Venture Capital 2008/2009 is an authoritative, insider's perspective securing venture capital and achieving growth in the biotech industry for VCs, entrepreneurs, and industry executives. Featuring managing partners at top VC firms and CEOs of funded biotech companies, these experts provide key strategies for all stages of an investment with a focus on raising capital, establishing valuations, determining exit strategies, and structuring deals. From spotting opportunities and evaluating potential ROI to increasing fundraising and growing the company, these specialists offer strategies for building a management team, assessing potential exit scenarios, and navigating market opportunities. The different niches presented and the breadth of perspectives represented enable readers to get inside some of leading minds of today, as these insiders offer up their thoughts around the keys to successful deal-making in this ever-evolving industry.
Essential Biotech Investment Guide, The: How To Invest In The Healthcare Biotechnology And Life Sciences Sector by Tang Mark Chilung Pdf
This invaluable book tells the reader how to invest in the healthcare biotechnology and life sciences sector, one of the fast-growing sectors of the US economy. Aimed at biotech investors as well as bioentrepreneurs and venture capitalists, it has been written from the perspectives of risk management and asset management/allocation. It strives to teach readers how to fish, rather than giving them fish. The author has over ten years of Wall Street experience in biotech research, investment banking and asset management. He holds an MBA in Finance and a PhD in Biochemistry.
The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them Praise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan's book, punctuated with his personal experience and opinions, is a good place to start." —Chris Blackwell, Chief Executive, Vectura Group plc "A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians." —Steve Winokur, Managing Director, CanaccordAdams "A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value." —Dr L.M. Allan, Director, Bioscience Enterprise Programme, University of Cambridge "A fabulous approach to a difficult topic." —Deirdre Y. Gillespie, MD, President & CEO, La Jolla Pharmaceutical Company
Financing in Life Sciences Biotech Companies by Christian Strassburger Pdf
Seminar paper from the year 2006 in the subject Business economics - Investment and Finance, grade: 1,3, Pforzheim University, course: Corporate Finance, 25 entries in the bibliography, language: English, abstract: Biotechnology is a more and more important field of research in present. Publicly we are currently confronted with many questions about the rights and wrongs within this field of science, like how to handle the issue of gene manipulation or stem cell research. However, biotechnology is more than just an accumulation of ethical questions and science - it is a whole industry and as such interesting for investors. The scope of this paper is not dealing with the topics discussed in glossy magazines, but it addresses the issues of corporate finance in biotechnology. In order to get an overview of the industry from a finance point of view, the industry has to be portrayed. Hence, this is the topic of chapter two. From the point of the investors, and therefore of the capital markets, the understandability of the segment biotechnology, and thus the availability of crucial information has to be ensured. Consequently the transparency of the biotechnology segment and of the individual enterprises, respectively, are the topics of the third chapter. The implications of this chapter have a strong impact on the valuation of biotechnological companies and the sector as a whole - a subject dealt with in chapter number four. The fifth chapter is concerned with the core topic of this paper and identifies and analyses different sources of finance for biotechnology enterprises. Thereby it is taking the point of view of the biotechnology firms and the potential investors. The paper is showing important difficulties and advantages connected with the different approaches. Additionally the chapter also describes and evaluates the risks of different options of investors. The paper is concluded with a summary of the findings in chapter six showing that investing into biotechno
Venture Capital Contracting and the Valuation of High-technology Firms by Joseph McCahery,Luc Renneboog Pdf
Venture capitalists are specialized intermediaries that channel capital to firms and professional services to companies that might otherwise be excluded from the corporate debt market and other sources of private finance. Venture capital financing is used to invest mainly in small and medium size firms with good growth and exit potential. Typically, venture capital firms concentrate in industries with a great deal of uncertainty, where the information gaps among entrepreneurs and venturecapitalist are commonplace. Venture capital firms are active in sectors with a high informational opacity and agency costs. These ventures are identified as financially constrained. Start-up firms rely on venture capital as one of their main sources of funding. Recent empirical research has found that the effect of venture capital on the success of these ventures is considerable. The value of venture capital investment is borne out by the figures which show that venture capital backed-firms grow on average twice as fast as those not backed by venture capital firms. The debate on the development of an efficient venture capital market has forced us to consider which financial instruments, legal rules, labour laws, contracts, and other institutional structures are necessary to create a venture capital market. The contributions to this book have offered insights on the structure of venture capital fund financial contracts, the screening, monitoring and staging of potential investments, the importance of partnership and other legal business forms for investors and start-up firms, the funding of innovation, the valuation of investments, and the exit routes for venture capitalists. The essays in this volume, which draw upon international evidence and ideas from financial economics and law, contribute to further research on the relationship between venture capitalists and entrepreneurs. This collection analyses the main legal and contracting structures in the venture capital cycle. Exploring the differences between the US and European venture capital markets, it focuses on diverse organizational and contractual techniques, such as staged finance, convertible securities, board functions and other forms of control, and the role of exit. Theoretical chapters examine the valuation of entrepreneurial firms and the liquidiation preference in convertible securities. Finally, the book assesses the importance of the IPO market for entrepreneurs, investors and venture capitalists alike.
Health Care Venture Capital Best Practices by Aspatore Books Pdf
Health Care Venture Capital Best Practices is an authoritative, insiders perspective on the ins and outs of health care venture capital for VCs, entrepreneurs, and industry executives. Featuring managing partners at top VC firms and CEOs of funded health care companies, these experts provide best practices for venture capitalists and entrepreneurs at all stages of an investment with a focus on raising capital, establishing valuations, determining exit strategies, and structuring deals. From spotting opportunities in the industry to developing a solid leadership plan, these industry leaders discuss characteristics that make a good partner, key tools and methods for determining valuations, strategies for conducting due diligence, and negotiation techniques to produce a successful deal. These seasoned experts reveal their advice for increasing fund-raising, assessing potential ROI, evaluating the timeline of a deal, and understanding management team criteria, as well as provide insight for hedging risks and avoiding common mistakes. Additionally, the authors offer strategies for overcoming challenges, dealing with biotechnology risks, and investing in medical device companies. The different niches presented and the breadth of perspectives represented enable readers to get inside some of the leading minds of today, as these insiders offer up their thoughts around the keys to successful deal-making in this rapidly evolving industry.
Inside the Minds: Biotechnology Deals is an authoritative, insider's perspective on the issues surrounding biotech deals, including mergers and acquisitions, collaborations, and the future of doing successful deals. Featuring lawyers, CEOs of funded biotech companies, and venture capitalists who invest in them, this book provides a broad, yet comprehensive overview of the art of doing successful deals from the experts themselves. From finding and capitalizing on opportunities to completing the deal, these authors articulate the finer points around doing biotech deals now and what will hold true into the future. The different niches represented and the breadth of perspectives presented enable readers to get inside some of the great legal minds of today as experts offer up their thoughts around the keys to success within this fascinating area.About Inside the Minds:Inside the Minds provides readers with proven business intelligence from C-Level executives (Chairman, CEO, CFO, CMO, Partner) from the world's most respected companies nationwide, rather than third-party accounts from unknown authors and analysts. Each chapter is comparable to an essay/thought leadership piece and is a future-oriented look at where an industry, profession or topic is headed and the most important issues for the future. Through an exhaustive selection process, each author was hand-picked by the Inside the Minds editorial board to author a chapter for this book.This book is by: Lee R. Brettman, M.D., FACP, Dynogen Pharmaceuticals, Inc.??Successful Strategies for Biotech Deals?Manish N Chapekar, Montreux Equity Partners??Building Successful Biotech Deals?Daniel Devine, Acceptys, Inc.??The Art of the Deal?Mark I. Gruhin, Schmeltzer, Aptaker & Shepard, PC??Mergers and Acquisitions, Collaborations, and Partnerships?James T. Gunton, NJTC Venture Fund??Strategies for Successful Deals?Johnny Humphreys, Gen Prime??Finding Success in Biotech?Roland H. Johnson, Piedmont Pharmaceuticals LLC??Making Your Way Through Biotech Dealings?Thomas G. Klopack, Self Employed, Former CEO of Aclara Biosciences??Keys to Success in Biotechnology?Gerard J. McGarrity, Ph.D., Intronn Inc.??Successful Biotech Deals?Mark Schwartz , Ph.D., Bayhill Therapeutics??Biotech Deal Strategies?Abhi-Shek Jain, WTP Capital, LLC??Secrets to Success?Alexis V. Lukianov, NuVasive, Inc.??Finding and Capitalizing on Opportunities?
Raising Venture Capital For Biotech Companies by Thomas Tscherning,Jesper Zeuthen Pdf
Gain access to biotech venture capital as efficiently as possible by doing the right things from the beginning of your fundraising. This book includes a collection of improvements that will increase your rate of success on receiving capital without loosing your shirt in the process. From how to make the biotech investor listen to you to the reasons deals get killed and everything in between, including a wealth of appendix material that guides readers through the basic slides of a presentation, the ins and outs of term sheets, key terms and more, this book is a must-read for anyone in need of funding. Topics covered include: - which business plans fail and why - understanding the interests of the investor - planning for solvency and liquidity - knowing and minimizing product risk - the value of a scientific advisory board - important points around patents - questions frequently posed by investors - questions to extend to biotech investors - what constitutes a good biotech deal - when is a bad time to try and close one - how to close your presentation, the deal and each round successfully and more.
